Daiichi Pharmaceutical Co. Ltd.
www.daiichipharm.co.jp
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Daiichi Pharmaceutical Co. Ltd.
From Whiskey To Cancer Drugs: George Nakayama’s Unusual Journey
From extricating Daiichi Sankyo from the Ranbaxy acquisition to enabling the rapid development of blockbuster Enhertu, George Nakayama has had a winding career path through multiple key strategic positions and decisions. He shares his experience and insights, and a good dose of humor, in this exclusive interview.
BioNTech Eyes First Oncology Approvals By 2026
The biotech's CEO told the J.P. Morgan Healthcare Conference that the company aims to have multiple oncology products on the market by 2029, but it plans to retain a large presence in vaccines as well.
Five Key Takeaways From Merck’s Q2 Earnings Release
Keytruda and Gardasil lead Merck’s growth story, although Lagevrio’s ongoing decline placed a drag on quarterly performance. Lung cancer is driving Keytruda’s momentum outside the US.
Exelixis Looks To Early-Stage Option Rights As Low-Risk Pipeline Expansion Play
The maker of Cabometyx wants to expand its oncology pipeline via deal-making but is wary of the high attrition rate in cancer. Option deals with Cybrexa and Sairopa may avoid some of that risk.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice